NVCR

1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M

YTD YTD

1 Year 1Y

5 Years 5Y

About NovoCure Ltd

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure's commercialized products are approved for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer.
CEO
Asaf Danziger
Employees
1023
Headquarters

Forum
No 4 Grenville Street, Saint Helier JE2 4UF
Phone: 441534756700
www.novocure.com

News

What''s Driving NovoCure Ltd''s Surprising 29% Stock Rally?
May 15, 2024 16:16pm

What''s Driving NovoCure Ltd''s Surprising 29% Stock Rally?


Source:GuruFocus
Is NovoCure (NVCR) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
May 15, 2024 01:14am

Is NovoCure (NVCR) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap


Source:GuruFocus
Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
May 14, 2024 11:08am

If you’re wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price. Yet, the reality is that the average annual S&P 500 return is approximately 10%. At that rate the law of 72 states that an investor can expect their capital to double roughly every 7 years. Thus, those seeking 100% returns by 2025 will have to take some risks. There is effectively zero chance that an average strategy will double an investor’s returns within that time frame. That doesn’t mean an investor should place 100% of their capital in Risky stocks such as those discussed below. Instead, a more pragmatic approach limiting exposure to the neighborhood of 10% is prudent. In that way an investor can achieve annual returns above that aforementioned 10% threshold while limiting downside exposure. Let’s learn about a handful of stocks that make sense in that regard. Stocks to Buy: Arrowhead Pharmaceuticals (ARWR) Source: Pavel Kapysh / Shutterstock.com Arrowhead Pharmaceuticals (NASDAQ: ARWR ) is a relatively well-established pharmaceutical stock with a deep pipeline of drugs representing current and future potential.


Source:InvestorPlace
NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03, 2024 22:03pm

No summary available.


Source:Seeking Alpha
BioPharma Credit announces senior loan to Novocure for up to US$400m
May 03, 2024 06:37am

BioPharma Credit (BPCR) is providing debt financing to Novocure Luxembourg S.a.r.l. through a senior secured loan agreement. BPCR will invest up to US$200m and BioPharma-V will invest up to an additional US$200m in parallel, with BPCR acting as collateral agent. Under the terms of the transaction, the Company will invest up to US$200m across four tranches: Tranche […] The post BioPharma Credit announces senior loan to Novocure for up to US$400m appeared first on QuotedData .


Source:QuotedData
NovoCure (NVCR) Q1 2024 Earnings Call Transcript
May 03, 2024 05:00am

NVCR earnings call for the period ending March 31, 2024.


Source:The Motley Fool
Novocure secures $400 million credit facility
May 02, 2024 19:01pm

https://www.investing.com/news/company-news/novocure-secures-400-million-credit-facility-93CH-3415612


Source:Investing.com
NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024
May 02, 2024 15:56pm

NovoCure (NASDAQ: NVCR ) just reported results for the first quarter of 2024. NovoCure reported earnings per share of -36 cents. This was above the analyst estimate for EPS of -42 cents. The company reported revenue of $138.50 million. This was 5.37% better than the analyst estimate for revenue of $131.45 million. InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com. More From InvestorPlace The #1 AI Investment Might Be This Company You’ve Never Heard Of Musk’s “Project Omega” May Be Set to Mint New Millionaires. Here’s How to Get In. It doesn’t matter if you have $500 or $5 million.


Source:InvestorPlace
NovoCure Limited (NVCR) Q1 2024 Earnings Call Transcript
May 02, 2024 15:43pm

NovoCure Limited (NASDAQ:NASDAQ:NVCR) Q1 2024 Earnings Conference Call May 2, 2024 8:00 AM ETCompany ParticipantsIngrid Goldberg - Investor RelationsBill…


Source:Seeking Alpha
NovoCure Limited 2024 Q1 - Results - Earnings Call Presentation
May 02, 2024 13:37pm

No summary available.


Source:Seeking Alpha